论文部分内容阅读
目的:观察瑞舒伐他汀对颈动脉粥样硬化的药理作用与临床应用价值。方法:随机抽取本院2013年3月-2014年5月收治的64例动脉粥样硬化患者的临床资料,按照入院先后顺序将其分为对照组与观察组,各32例,对照组患者给予阿司匹林治疗,观察组应用瑞舒伐他汀治疗,观察血脂及颈动脉内膜中层厚度变化。结果:观察组总胆固醇(TC)、颈动脉内膜中层厚度(IMT)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)等指标改善情况均优于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀治疗动脉粥样硬化能够显著改善患者的高血脂与动脉粥样硬化病理变化。
Objective: To observe the pharmacological effects of rosuvastatin on carotid atherosclerosis and its clinical value. Methods: A total of 64 patients with atherosclerosis admitted to our hospital from March 2013 to May 2014 were randomly divided into control group and observation group according to the order of admission, and each group was given 32 patients Aspirin treatment, the observation group with rosuvastatin treatment, the observed lipid and carotid artery intima-media thickness changes. Results: The improvement of total cholesterol (TC), IMT, LDL-C and triglyceride in the observation group were better than those in the control group (P <0.05 ). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Rosuvastatin treatment of atherosclerosis can significantly improve the patients with hyperlipidemia and atherosclerosis pathological changes.